ne 30, 2013 was $788,112, compared to $656,953 for the same period in 2012. This represents an increase of $131,159, or approximately 20%, and is the result of a decrease in cost of sales in four of our six business segments. Gross profit for the six-month period ended June 30, 2013 was $1,367,632, compared to $1,327,693, for the same period in 2012. This represents an increase of $39,939, or approximately 3%.
Operating expenses decreased to $1,081,655 for the three months ended June 30, 2013, from $1,194,329 for the same period in 2012. This decrease of $112,674, or approximately 9%, is the result of overall operating expense reductions as a result of management's continued efforts to reduce discretionary costs where possible and secure beneficial pricing on general operating purchases. Operating expenses were $2,248,456 for the six-month period ended June 30, 2013, compared to $2,471,264 for the same period in 2012. This represents a decrease of $222,808 or approximately 9%.
This decrease is largely attributable to reduced spending on research and development costs for the planning and construction of the de-conversion facility we plan to construct in New Mexico.
Research and development expense incurred, with regard to the planning and construction of the proposed de-conversion facility we plan to build in New Mexico, decreased by approximately 24%, to $210,850 for the three months ended June 30, 2013, from $279,073, for the same period in 2012. This $68,223 reduction in expenditures is the result of current limited funding available to invest in the project; however, if and when funds do become available, we expect to increase our investment in this area.
Our net loss for the three months ended June 30, 2013 was $399,210, compared to $515,132 for the same period in 2012. This is a decrease in net loss of $115,922, or approximately 23%, and is primarily the result o
Page: 1 2 3 4 5 6 7 Related medicine technology :1
|SOURCE International Isotopes Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade2
. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm3
. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium4
. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies5
. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.6
. Chindex International, Inc. to Report First Quarter 2012 Financial Results7
. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH8
. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research9
. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline10
. Bacterin International Signs Its Third National GPO Contract with Novation11
. SurgLine International, Inc. Chief Executive Officer, Thomas Toland, Exclusive Interview on Stock Traders Talk Radio